Interleukin-6 is a cofactor for the growth of myeloid cells from human bone marrow aspirates but does not affect the clonogenicity of myeloma cells in vitro
- 1 December 1990
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 76 (4) , 476-483
- https://doi.org/10.1111/j.1365-2141.1990.tb07903.x
Abstract
Summary Several groups have claimed that IL-6 is a growth factor for human myeloma cells in vitro. Bone marrow aspirates from 30 patients at different stages of treatment with VAMP/high dose melphalan, were examined for myeloma colony formation (MY-CFU,) using a clonogenic assay in vitro. Myeloma cells from 16/30 patients produced MY-CFUc in our assay system, which uses heavily irradiated HL60 cells as an underlay in soft agar. These heavily irradiated cells were shown to be essential for the inhibition of granulocyte-macrophage colonies (GM-CFUc). The addition of recombinant human IL-6 (10 ng/plate) reduced the number of bone marrow samples which produced MY-CFUc from 16 to six. Furthermore, the addition of antibody to IL-6 (1 μg/plate) failed to inhibit MY-CFUc from 6/7 samples. Conditioned medium from human peripheral blood mono-nuclear cells (PBMC-CM) contains approximately 2 ng/ml IL-6 and can be used to stimulate the growth and maintenance of the B9 murine IL-6 dependent hybridoma cell line. Kecombinant human IL-6 supported the growth of B9 cells in a clonogenic assay and growth was inhibited by anti-IL-h in the presence of rhIL-6 or PBMC-CM. Mononuclear cells from a second group of myeloma patients were cultured in soft agar in a mixture of PBMC-CM and fresh growth medium. Nine of the 10 samples produced myeloid colonies which consisted of granulocytes, monocytes and macrophages and the number of colonies was reduced by at least 50% in 6/8 samples when anti-IL-6 was added to the cultures. In no instance were MY-CFUc produced. Also, conditioned medium from the bladder carcinoma cell line 5637. which is used routinely as a source of granulocyte-macrophage colony stimulating factor (GM-CSF), contains approximately 4 ng/ml IL-6. Although rhIL-6 failed to stimulate GM-CFUc in the absence of other growth factors, addition of anti-IL-6 to cultures containing a suboptimal amount of 5637-CM reduced the number of colonies by 50%. These data provide evidence that IL-6 is a cofactor for the growth of myeloid precursors but does not affect the proliferation of human myeloma cells in vitro.Keywords
This publication has 30 references indexed in Scilit:
- The Role of Plasmacytoma Growth Factor in the in Vitro Responses of Murine Plasmacytoma CellsAnnals of the New York Academy of Sciences, 1989
- Biochemical and Biological Properties of Human HPGF/IL‐6Annals of the New York Academy of Sciences, 1989
- INCREASE IN CLONOGENIC TUMOUR CELLS IN BONE MARROW OF PATIENTS WITH MULTIPLE MYELOMA TREATED WITH VINCRISTINE, DOXORUBICIN, AND METHYLPREDNISOLONEThe Lancet, 1988
- A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitroBritish Journal of Haematology, 1988
- The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells.The Journal of Experimental Medicine, 1988
- Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression.The Journal of Experimental Medicine, 1987
- Role of immune stimulation in the etiology of multiple myeloma: A case control studyAmerican Journal of Hematology, 1987
- Production of hybridoma growth factor by human monocytesEuropean Journal of Immunology, 1987
- Monoclonal gammapathies in patients undergoing immunosuppressive treatment after renal transplantationClinical Immunology and Immunopathology, 1985
- The effect of oxygen tension on haemopoietic and fibroblast cell proliferation in vitroJournal of Cellular Physiology, 1978